(Q28278381)

https://doi.org/10.1016%2FS0065-230X%2806%2996008-4

9 April 2017

0 references

1 reference

2

Paul Workman

1 reference

9 April 2017

author name string

Debashis Sarker

series ordinal

1

1 reference

https://doi.org/10.1016%2FS0065-230X%2806%2996008-4

9 April 2017

language of work or name

English

0 references

publication date

2007

0 references

2006

1 reference

https://doi.org/10.1016%2FS0065-230X%2806%2996008-4

Advances in Cancer Research

9 April 2017

published in

1 reference

https://doi.org/10.1016%2FS0065-230X%2806%2996008-4

9 April 2017

volume

96

0 references

page(s)

213-68

0 references

213-268

1 reference

https://doi.org/10.1016%2FS0065-230X%2806%2996008-4

Use of positron emission tomography in anticancer drug development

9 April 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Intracellular signal transduction pathway proteins as targets for cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Ethics of phase 1 oncology studies: reexamining the arguments and data

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Oncogenic PI3K deregulates transcription and translation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

POSITRON EMISSION TOMOGRAPHY FOR IN-VIVO MEASUREMENT OF REGIONAL BLOOD FLOW, OXYGEN UTILISATION, AND BLOOD VOLUME IN PATIENTS WITH BREAST CARCINOMA

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Genetically engineered models have advantages over xenografts for preclinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

The TOR pathway: a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

High-throughput crystallography for lead discovery in drug design.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Mutation of the PIK3CA gene in ovarian and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Assays for pharmacodynamic analysis of histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Gene expression microarray technologies in the development of new therapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotope.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Functional imaging in phase I studies: decorations or decision making?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Imaging and other biomarkers in early clinical studies: one step at a time or re-engineering drug development?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Targeting epidermal growth factor receptor--are we missing the mark?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Targeting EGFR in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Prognostic and predictive value of p53 and p21 in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Current development of mTOR inhibitors as anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Clinical biomarkers in drug discovery and development

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

1 reference

7 January 2021

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Antivascular cancer treatments: imaging biomarkers in pharmaceutical drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

The discovery of receptor tyrosine kinases: targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

PDGFRA activating mutations in gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Exploiting the PI3K/AKT pathway for cancer drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Back to the drawing board on immunohistochemistry and predictive factors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

New target, new drug, old paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Rapamycins: mechanism of action and cellular resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Mapping normal and cancer cell signalling networks: towards single-cell proteomics

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic Antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Conditional mouse models of sporadic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Imaging apoptosis in vivo using 124I-annexin V and PET.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

New science-based endpoints to accelerate oncology drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Can the pharmaceutical industry reduce attrition rates?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Nontoxicity endpoints in phase I trial designs for targeted, non-cytotoxic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Clinical trial designs for cytostatic agents: are new approaches needed?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Tyrosine kinases as targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Initial sequencing and analysis of the human genome

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

International Workshop on Standardization in Clinical Magnetic Resonance Spectroscopy Measurements: proceedings and recommendations.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Expression of pRB, cyclin/cyclin-dependent kinases and E2F1/DP-1 in human tumor lines in cell culture and in xenograft tissues and response to cell cycle agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Biomarkers in cancer staging, prognosis and treatment selection

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

HSP90 as a new therapeutic target for cancer therapy: the story unfolds

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Genes and Proteins Governing the Cellular Sensitivity to HSP90 Inhibitors: A Mechanistic Perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Discovery and development of pyrazole-scaffold Hsp90 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

TORward AKTually useful mouse models

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Use of proteomic patterns in serum to identify ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Translating cancer genomics into clinical oncology.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Trends in development and approval times for new therapeutics in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Magnetic resonance detects metabolic changes associated with chemotherapy-induced apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

High frequency of mutations of the PIK3CA gene in human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Contributions of human tumor xenografts to anticancer drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Opportunities and challenges in the development of kinase inhibitor therapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Will mTOR inhibitors make it as cancer drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

A gene expression database for the molecular pharmacology of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

TOR, a central controller of cell growth

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

PIK3CA is implicated as an oncogene in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Imaging proliferation in vivo with [F-18]FLT and positron emission tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

HERe-2 stay: the continuing importance of translational research in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Putting the rap on Akt.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Use of isogenic human cancer cells for high-throughput screening and drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Validation overview of bio-analytical methods

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

ADMET in silico modelling: towards prediction paradise?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

A gene-expression signature as a predictor of survival in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Cancer modeling in the modern era: progress and challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

The Sequence of the Human Genome

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

HSP90 and the chaperoning of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Challenges of PK/PD measurements in modern drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Genomics and the second golden era of cancer drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Genomic profiling of cancer: what next?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Translating basic cancer research into new cancer therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition)

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Drugging the PI3 kinome.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

Identification of new biomarkers for clinical trials of Hsp90 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996008-4

7 January 2021

10.1016/S0065-230X(06)96008-4

Identifiers

DOI

1 reference

https://doi.org/10.1016%2FS0065-230X%2806%2996008-4

release_7uuae5igp5fvlia6ydigvhqx3i

9 April 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7uuae5igp5fvlia6ydigvhqx3i

24 November 2022